Journal Article
. 2018 Aug;25(11).
doi: 10.1245/s10434-018-6687-z.

Breast Cancers of Special Histologic Subtypes Are Biologically Diverse

Audree B Tadros 1 Hannah Y Wen 2 Monica Morrow 3 
Affiliations
  • PMID: 30094484
  •     34 References
  •     4 citations

Abstract

Background/Objective: Cancers classified as "special histologic subtypes" are felt to have a good prognosis. We used the 21-gene Oncotype DX Breast Recurrence Score® multigene assay to examine prognostic variation within special histologic subtypes. We also examined the Recurrence Score® (RS) distribution among the more common ductal (IDC) and lobular (ILC) cancers.

Methods: 610,350 tumor specimens examined in the Genomic Health clinical laboratory from 2/2004 to 8/2017 were included. Specimen histology was classified centrally using a single H&E slide and World Health Organization criteria. RS distribution (low < 18, intermediate 18-30, and high ≥ 31) was compared among histologic subtypes.

Results: Median patient age was 60 years (IQR 51-67); 80% were node negative. Most patients had low RS results (59.2%); only 9.5% had high results. The lowest mean RS was seen in the papillary subtype (11); the highest in the IDC group (18.4). Mean RS for all special subtypes was lower than that of IDC patients. When the high RS threshold was decreased from 31 to 25, as used in the TAILORx and RxPONDER trials, the number of high RS-result patients increased from 9.5% to 16.8%. Patients with ILC had a lower mean RS result than patients with IDC, 16.5 versus 18.4.

Conclusion: There is substantial diversity in predicted prognosis among patients with cancers classified as special histologic subtypes, with 12-25% having intermediate RS results and 0.5-9% having high RS results. Pending further definition of the role of chemotherapy for patients with intermediate RS results by TAILORx and RxPONDER, the RS result may help to inform systemic therapy decisions in these patients.

Pure mucinous carcinomas of breast: morphologic features and prognostic correlates.
F Clayton.
Hum Pathol, 1986 Jan 01; 17(1). PMID: 3002950
Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.
Scott D Ramsey, William E Barlow, +6 authors, Gabriel N Hortobagyi.
Contemp Clin Trials, 2012 Sep 25; 34(1). PMID: 23000081    Free PMC article.
Review.
Lobular breast carcinoma and its variants.
Emad A Rakha, Ian O Ellis.
Semin Diagn Pathol, 2010 Mar 24; 27(1). PMID: 20306830
Review.
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
Michael J Hassett, Samuel M Silver, +12 authors, Jane C Weeks.
J Clin Oncol, 2012 May 16; 30(18). PMID: 22585699    Free PMC article.
Invasive cribriform carcinoma of the breast.
D L Page, J M Dixon, +2 authors, H J Stewart.
Histopathology, 1983 Jul 01; 7(4). PMID: 6884999
Invasive lobular carcinomas of the breast--the prognosis of histopathological subtypes.
R S du Toit, A P Locker, +3 authors, R W Blamey.
Br J Cancer, 1989 Oct 01; 60(4). PMID: 2803932    Free PMC article.
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
Otto Metzger Filho, Anita Giobbie-Hurder, +12 authors, Aron Goldhirsch.
J Clin Oncol, 2015 Jul 29; 33(25). PMID: 26215945    Free PMC article.
Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.
Bernhard C Pestalozzi, David Zahrieh, +13 authors, International Breast Cancer Study Group.
J Clin Oncol, 2008 May 07; 26(18). PMID: 18458044
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
Catherine M Kelly, Savitri Krishnamurthy, +4 authors, Lajos Pusztai.
Cancer, 2010 Jul 29; 116(22). PMID: 20665886
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Gulisa Turashvili, Edi Brogi, +4 authors, Hannah Y Wen.
Breast Cancer Res Treat, 2017 Jun 04; 165(1). PMID: 28577081    Free PMC article.
Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?
Séverine Guiu, Anita Wolfer, +4 authors, Maryse Fiche.
Crit Rev Oncol Hematol, 2014 Aug 19; 92(3). PMID: 25129506
Review.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Lyndsay N Harris, Nofisat Ismaila, +11 authors, American Society of Clinical Oncology.
J Clin Oncol, 2016 Feb 10; 34(10). PMID: 26858339    Free PMC article.
Highly Cited. Review.
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Benjamin O Anderson, +28 authors, Rashmi Kumar.
J Natl Compr Canc Netw, 2016 Mar 10; 14(3). PMID: 26957618
Highly Cited.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Michaela A Dinan, Xiaojuan Mi, +2 authors, Lesley H Curtis.
JAMA Oncol, 2015 Aug 28; 1(8). PMID: 26313372
Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution.
Enrico Orvieto, Eugenio Maiorano, +7 authors, Giuseppe Viale.
Cancer, 2008 Aug 16; 113(7). PMID: 18704988
An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.
Jesse L Felts, Junjia Zhu, +2 authors, Cristina I Truica.
Breast J, 2017 Jan 18; 23(6). PMID: 28097781
21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.
Jagar Jasem, Arya Amini, +4 authors, Peter Kabos.
J Clin Oncol, 2016 Mar 24; 34(17). PMID: 27001563    Free PMC article.
Infiltrating lobular carcinoma of the breast.
J M Dixon, T J Anderson, +2 authors, S W Duffy.
Histopathology, 1982 Mar 01; 6(2). PMID: 7076138
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up.
I O Ellis, M Galea, +3 authors, C W Elston.
Histopathology, 1992 Jun 01; 20(6). PMID: 1607149
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Michaela L Tsai, Tamera J Lillemoe, +5 authors, Karen K Swenson.
Clin Breast Cancer, 2015 Sep 20; 16(1). PMID: 26385397
Tubular carcinoma of the breast. A long term follow-up.
P H Carstens, R A Greenberg, D Francis, H Lyon.
Histopathology, 1985 Mar 01; 9(3). PMID: 2987100
Comparison of Oncotype DX Recurrence Score by Histologic Types of Breast Carcinoma.
Philip E Bomeisl, Cheryl L Thompson, Lyndsay N Harris, Hannah L Gilmore.
Arch Pathol Lab Med, 2015 Dec 01; 139(12). PMID: 26619027
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.
Sunil S Badve, Frederick L Baehner, +13 authors, Joseph A Sparano.
J Clin Oncol, 2008 May 20; 26(15). PMID: 18487567
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Tubular carcinoma of the breast.
H S Cooper, A S Patchefsky, R A Krall.
Cancer, 1978 Nov 01; 42(5). PMID: 214219
Outcome of special types of luminal breast cancer.
M Colleoni, N Rotmensz, +13 authors, G Viale.
Ann Oncol, 2011 Nov 01; 23(6). PMID: 22039080
Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants.
E R Fisher, S Anderson, C Redmond, B Fisher.
Cancer, 1993 Apr 15; 71(8). PMID: 8453574
Prognosis in infiltrating lobular carcinoma. An analysis of "classical" and variant tumors.
D DiCostanzo, P P Rosen, +2 authors, M Lesser.
Am J Surg Pathol, 1990 Jan 01; 14(1). PMID: 2153007
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
Allison W Kurian, Irina Bondarenko, +7 authors, Steven J Katz.
J Natl Cancer Inst, 2017 Dec 14; 110(5). PMID: 29237009    Free PMC article.
Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients.
Matthew G Hanna, Ira J Bleiweiss, Anupma Nayak, Shabnam Jaffer.
Int J Breast Cancer, 2017 Feb 09; 2017. PMID: 28168058    Free PMC article.
Vinculin Force Sensor Detects Tumor-Osteocyte Interactions.
Fangjia Li, Andy Chen, +9 authors, Jing Liu.
Sci Rep, 2019 Apr 06; 9(1). PMID: 30948840    Free PMC article.
ASO Author Reflections: Biological Diversity of Histologic Subtypes.
Audree B Tadros, Monica Morrow.
Ann Surg Oncol, 2018 Oct 10; 25(Suppl 3). PMID: 30298319    Free PMC article.
The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes.
Jun Wang, Zhen-Yu He, +3 authors, San-Gang Wu.
Front Genet, 2019 Jan 09; 9. PMID: 30619463    Free PMC article.
Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.
Amy E McCart Reed, Lauren Kalinowski, Peter T Simpson, Sunil R Lakhani.
Breast Cancer Res, 2021 Jan 09; 23(1). PMID: 33413533    Free PMC article.
Review.